Global Oncology Academy

Squamous Cell Carcinoma of the Head and Neck (SCCHN): Focus on Recurrent/Metastatic Disease

    The management of metastatic cancers has changed significantly over the last decade with improved understanding of its underlying pathophysiology a...
    • Overview

      The management of metastatic cancers has changed significantly over the last decade with improved understanding of its underlying pathophysiology and signal pathways. However, a significant proportion of patients with metastatic colorectal cancer or metastatic squamous cell carcinoma of the head and neck has a poor prognosis, in many cases due to late presentation. For those patients, cure is typically not possible; treatment options can prolong life and improve symptoms.  Thus, long-term survival rates in these metastatic settings, while improving, remain unacceptably low.

      Despite advances, the management of patients with metastatic disease continues to present challenges for clinicians. As innovative focused therapeutic options become available and treatment paradigms evolve, the need to discern when and how to incorporate these promising agents into clinicians’ armamentarium presents a great educational need. Moreover, continuing advances in our understanding of cancer pathophysiology, molecular pathways, the optimal and sequential use of targeted therapies in the context of chemotherapy and radiotherapy in the metastatic setting and the therapeutic potential of investigational agents currently being explored for various cancers, suggest educational and clinical practice gaps that must be effectively addressed to further improve outcomes in patients with cancer.

      Given this information, Siyemi Learning in partnership with Prova Education, presents this module titled “Squamous Cell Carcinoma of the Head and Neck (SCCHN): Focus on Recurrent/Metastatic Disease”. This module reviews the diagnosis and staging of SCCHN, the decision-making process in the selection of cytotoxic therapies, an assessment of current treatment modalities, overcoming resistance to platinum therapy and next-generation therapies for the treatment of recurrent/metastatic SCCHN.

    • Learning Objectives

      At the completion of this module, participants will be better able to:

      1. Describe appropriate steps in the diagnosis and staging of SCCHN
      2. Explain the decision-making process and factors in the selection of cytotoxic therapy for recurrent/metastatic SCCHN
      3. Assess the relative efficacy of treatment modalities for locoregional/locoregionally advanced SCCHN
      4. Evaluate the potential clinical applicability of next-generation therapies for the treatment of SCCHN
    • Commercial Support

      This activity is supported by an independent educational grant from Merck KGaA, Darmstadt, Germany.
       
      Original Release Date: 5 February 2015
      Expiration Date: 5 February 2017

    • Disclosure of Conflicts of Interest

      COURSE DIRECTOR

      Jan B. Vermorken, MD, PhD
      Emeritus Professor of Oncology
      Department of Medical Oncology 
      Antwerp University Hospital 
      Edegem, Belgium
      Financial Relationship Disclosure
      Consultant: Amgen, Genentech, Merck Serono, Shionogi      
      Commercial Interest Speakers Bureau: Merck Serono

      AUTHORS

      Joel Guigay, MD, PhD
      Director of Cancer Center
      Centre Antoine Lacassagne
      Nice, France
      Financial Relationship Disclosure
      Contracted Research: Boehringer-Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Merck Serono

      Makoto Tahara, MD, PhD
      Department of Head and Neck Medical Oncology
      National Cancer Center Hospital East
      Chiba, Japan
      Financial Relationship Disclosure
      Consultant: Eisai, Merck Serono              
      Commercial Interest Speakers Bureau: Bristol-Myers Squibb, Merck Serono                       
      Contracted Research: Boehringer-Ingelheim, Eisai

      Jan B. Vermorken, MD, PhD
      Emeritus Professor of Oncology
      Department of Medical Oncology 
      Antwerp University Hospital 
      Edegem, Belgium
      Financial Relationship Disclosure
      Consultant: Amgen, Genentech, Merck Serono, Shionogi      
      Commercial Interest Speakers Bureau: Merck Serono

      REVIEWER

      Jennifer Grandis, MD, FACS
      Vice Chair for Research 
      Professor of Otolaryngology & Pharmacology 
      University of Pittsburgh School of Medicine 
      Program Leader, Head & Neck Cancer Program 
      University of Pittsburgh Cancer Institute 
      Pittsburgh, PA - USA
      Financial Relationship Disclosure
      Grant/Research Support: Bristol-Myers Squibb, Novartis

    Facebook Comments

    NEW FEATURES: